PLX Aug 2024 5.000 call
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 5.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 0.0500 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 7 |
PR NewswireProtalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California. Mr. Bashan will provide senior biotech executives, busi
- GuruFocus.com
Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Despite a dip in revenue, Protalix BioTherapeutics progresses with promising clinical trials and maintains a robust cash reserve.
Insider MonkeyProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript May 10, 2024 Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2024 Financial and Business […]
